ST3
MCID: SPP010
MIFTS: 51

Suppressor of Tumorigenicity 3 (ST3)

Categories: Cancer diseases

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 56 71
Cervical Carcinoma 56 13 54 17
Cervical Carcinoma, Tumor-Suppressor Gene Involved in; Ccts 56
Cervical Carcinoma, Tumor-Suppressor Gene Involved in 56
Tumor-Suppressor Gene, Hela Cell Type; Tshl 56
Tumor-Suppressor Gene, Hela Cell Type 56
Cervix Carcinoma 71
Tshl 56
Ccts 56
St3 56

Classifications:



External Ids:

OMIM 56 191181
UMLS 71 C0302592 C1860658

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary : Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to in situ carcinoma and cervix uteri carcinoma in situ. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cellular Senescence (REACTOME). The drugs Vaccines and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

More information from OMIM: 191181

Related Diseases for Suppressor of Tumorigenicity 3

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 514)
# Related Disease Score Top Affiliating Genes
1 in situ carcinoma 31.3 TP53 MYC CDKN2A
2 cervix uteri carcinoma in situ 31.1 TP53 RB1 FHIT CDKN2A
3 cervical squamous cell carcinoma 31.0 TP53 MYC CDKN2A
4 cervix carcinoma 31.0 TP53 FHIT CDKN2A
5 chronic cervicitis 30.9 TP53 CDKN2A
6 familial retinoblastoma 30.8 TP53 RB1 CDKN2A
7 cervical adenocarcinoma 30.3 TP53 MYC CDKN2A CDKN1A
8 keratinizing squamous cell carcinoma 30.3 TP53 CDKN2A
9 papilloma 30.2 UBE3A TP53 RB1 CDKN2A CDKN1A
10 endocervical adenocarcinoma 30.0 TP53 CDKN2A CDKN1A
11 cervical mucinous adenocarcinoma 29.9 TP53 CDKN2A
12 retinoblastoma 29.9 TP53 RB1 MYC CDKN2A CDKN1A
13 oral cancer 29.7 TP53 FHIT CDKN2A
14 small cell cancer of the lung 29.7 TP53 RB1 BCL2
15 soft tissue sarcoma 29.7 TP53 BCL2
16 anogenital venereal wart 29.6 UBE3A TP53 RB1 CDKN2A
17 retinitis pigmentosa 11 29.6 TP53 MYC CDKN2A
18 adult t-cell leukemia 29.6 TP53 MYC CDKN2A
19 adenocarcinoma 29.6 TP53 RB1 MYC CDKN2A CDKN1A BCL2
20 vaginal cancer 29.5 UBE3A TP53 CDKN2A
21 anus cancer 29.5 UBE3A TP53 CDKN2A
22 vulva cancer 29.5 TP53 CDKN2A CA9
23 skin melanoma 29.5 TP53 CDKN2A CDKN1A
24 anal squamous cell carcinoma 29.5 TP53 CDKN2A
25 neuroblastoma 29.5 TP53 RB1 MYC CDKN2A CDKN1A
26 cervix disease 29.4 TP53 MYC CDKN2A
27 gallbladder cancer 29.3 TP53 MYC FHIT CDKN2A
28 myeloma, multiple 29.2 TP53 MYC CDKN2A CDKN1A
29 osteogenic sarcoma 29.0 TP53 RB1 MYC CDKN2A CDKN1A
30 endometrial cancer 29.0 TP53 RB1 MYC CDKN2A CDKN1A BCL2
31 breast ductal carcinoma 29.0 TP53 CDKN1A BCL2
32 colon adenocarcinoma 29.0 TP53 MYC CDKN1A BCL2
33 t-cell leukemia 29.0 TP53 RB1 MYC CDKN2A CDKN1A
34 squamous cell carcinoma 28.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
35 lymphoma 28.9 TP53 RB1 MYC CDKN2A BCL2
36 rhabdomyosarcoma 28.8 TP53 RB1 MYC CDKN2A CDKN1A
37 ductal carcinoma in situ 28.7 TP53 MYC CDKN2A CA9
38 basal cell carcinoma 28.7 TP53 CDKN2A CDKN1A BCL2
39 b-cell lymphoma 28.7 TP53 RB1 MYC CDKN2A CDKN1A BCL2
40 burkitt lymphoma 28.7 TP53 MYC CDKN2A CDKN1A BCL2
41 fibrosarcoma 28.6 TP53 MYC CDKN1A CA9
42 pancreatic adenocarcinoma 28.4 TP53 MYC CDKN2A CDKN1A BCL2
43 transitional cell carcinoma 28.3 TP53 FHIT CDKN2A CDKN1A CA9
44 kidney cancer 28.3 TP53 FHIT CDKN2A CDKN1A CA9
45 glioblastoma multiforme 28.2 TP53 RB1 MYC CDKN2A CDKN1A CA9
46 lung cancer susceptibility 3 28.2 TP53 RB1 MYC FHIT CDKN2A CDKN1A
47 myelodysplastic syndrome 28.1 TP53 MYC FHIT CDKN2A CDKN1A BCL2
48 nasopharyngeal carcinoma 28.1 TP53 MYC CDKN2A CDKN1A CA9 BCL2
49 pancreatic cancer 27.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
50 esophageal cancer 27.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:



Diseases related to Suppressor of Tumorigenicity 3

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM:

191181

GenomeRNAi Phenotypes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BCL2 CDKN1A CDKN2A RB1 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BCL2 CDKN1A CDKN2A MYC RB1 TP53

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.1 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
2 hematopoietic system MP:0005397 10.09 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
3 endocrine/exocrine gland MP:0005379 10.08 BCL2 CA9 CDKN1A CDKN2A MYC RB1
4 immune system MP:0005387 10.06 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
5 integument MP:0010771 10.02 BCL2 CDKN1A CDKN2A FHIT MYC RB1
6 mortality/aging MP:0010768 10.02 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
7 adipose tissue MP:0005375 9.99 BCL2 CDKN1A MYC PLIN3 RB1 TP53
8 hearing/vestibular/ear MP:0005377 9.85 BCL2 CDKN1A MYC RB1 TP53
9 neoplasm MP:0002006 9.76 BCL2 CDKN1A CDKN2A FHIT MYC RB1
10 muscle MP:0005369 9.73 BCL2 CDKN1A CDKN2A MYC RB1 TP53
11 no phenotypic analysis MP:0003012 9.43 CDKN1A CDKN2A MYC RB1 TP53 UBE3A
12 pigmentation MP:0001186 9.02 BCL2 CDKN2A MYC RB1 TP53

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Nelfinavir Approved Phase 3 159989-64-7 64143
7
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
8
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
9
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
10
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
11
Bevacizumab Approved, Investigational Phase 3 216974-75-3
12
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
13
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
16
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
17
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
18
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
19
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
20
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
22
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
23
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
24
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
25
Tirapazamine Investigational Phase 3 27314-97-2
26 Radiopharmaceuticals Phase 3
27 Antineoplastic Agents, Immunological Phase 3
28 Antimitotic Agents Phase 3
29 Antimetabolites Phase 3
30 Anti-Bacterial Agents Phase 2, Phase 3
31 Antibodies, Monoclonal Phase 3
32 Antibodies Phase 3
33 Immunoglobulins Phase 3
34 Topoisomerase Inhibitors Phase 3
35 Anti-Inflammatory Agents Phase 3
36 Autonomic Agents Phase 3
37 glucocorticoids Phase 3
38 Gastrointestinal Agents Phase 3
39 Endothelial Growth Factors Phase 3
40 Mitogens Phase 3
41 Immunoglobulin G Phase 3
42 Antiparasitic Agents Phase 2, Phase 3
43 Antiprotozoal Agents Phase 2, Phase 3
44 Antiemetics Phase 3
45 BB 1101 Phase 3
46 Antineoplastic Agents, Hormonal Phase 3
47 Anti-Infective Agents Phase 3
48 Immunologic Factors Phase 3
49 Antiviral Agents Phase 3
50
protease inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix Unknown status NCT01593306 Phase 3 Paclitaxel, Cisplatin;Cisplatin
3 Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
4 Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma Unknown status NCT01000415 Phase 3
5 Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
6 A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image Unknown status NCT00146458 Phase 3
7 A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy. Unknown status NCT01414517 Phase 3
8 Collaborative Corneal Transplantation Studies (CCTS) Completed NCT00000137 Phase 3
9 Phase III Study of S-1 + Cisplatin Compared With Single-agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix Completed NCT00770874 Phase 3 S-1 + Cisplatin (arm A);Cisplatin (arm B)
10 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
11 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
12 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
13 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
14 Preoperative Dexamethasone Reduces Postoperative Pain, Nausea and Vomiting Following Mastectomy for Breast Cancer. Completed NCT01116713 Phase 3 intravenous dexamethasone;Homologated placebo.
15 Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma" Completed NCT02083211 Phase 3 mAb Nimotuzumab
16 An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma Recruiting NCT03257267 Phase 3 REGN2810;Investigator Choice (IC) Chemotherapy
17 Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer Recruiting NCT02595554 Phase 3 Paclitaxel;Cisplatin
18 A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix Recruiting NCT03556839 Phase 3 Atezolizumab;Bevacizumab;Cisplatin;Paclitaxel
19 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
20 A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005) Recruiting NCT02629718 Phase 3 NACT (Paclitaxel + Cisplatin or carboplatin)
21 A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix. Recruiting NCT03256916 Phase 3 Nelfinavir;Cisplatin
22 Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer Recruiting NCT01561586 Phase 3 Weekly cisplatin with RT;Tri-weekly cisplatin with RT
23 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Recruiting NCT02669459 Phase 3 Imiquimod
24 Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma Active, not recruiting NCT01554397 Phase 2, Phase 3 Cisplatin
25 Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line. Active, not recruiting NCT03413579 Phase 3
26 Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma Active, not recruiting NCT00806117 Phase 3
27 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer. Active, not recruiting NCT01608451 Phase 3 Cholecalciferol;Inj. Progesterone
28 A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma Not yet recruiting NCT03086681 Phase 3 Endostar;DDP
29 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
30 Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix. Unknown status NCT01973101 Phase 2 Cisplatin;Gemcitabine;cisplatin
31 Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides Unknown status NCT00108875 Phase 1, Phase 2
32 An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma Unknown status NCT00292955 Phase 2 Cetuximab
33 An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix Unknown status NCT02492503 Phase 1, Phase 2 Paclitaxel and carboplatin;Paclitaxel and carboplatin
34 Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma. Unknown status NCT00039884 Phase 2 NESP - Novel Erythropoiesis Stimulating Protein
35 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Unknown status NCT01266460 Phase 2
36 Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix Unknown status NCT01117402 Phase 2
37 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
38 HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Cervical Carcinoma: Clinical Trial Completed NCT02523365 Phase 1, Phase 2
39 A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
40 A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer Completed NCT00257348 Phase 2 Capecitabine;Docetaxel
41 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
42 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
43 Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study Completed NCT00184093 Phase 1, Phase 2 Gemcitabine
44 Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial) Completed NCT00931164 Phase 1, Phase 2 Sodium Oxybate
45 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
46 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
47 Phase I/IIA, Open-Label, Safety, Tolerability, and Immunogenicity Study of INO-3112 Delivered by Electroporation (EP) in Women With Cervical Cancer After Chemoradiation for Newly Diagnosed Disease or Therapy for Recurrent and/or Persistent Disease Completed NCT02172911 Phase 1, Phase 2
48 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
49 A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT00499031 Phase 2
50 Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma Completed NCT00003445 Phase 2 docetaxel

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Genetic Tests for Suppressor of Tumorigenicity 3

Anatomical Context for Suppressor of Tumorigenicity 3

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

40
Cervix, Lymph Node, Breast, Testes, T Cells, Lung, Uterus

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(showing 10444, show less)
# Title Authors PMID Year
1
Interstitial deletion of 11q13 sequences in HeLa cells. 61 56
10959095 2000
2
Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. 61 56
7887426 1995
3
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 61 56
8041728 1994
4
Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. 61 56
1680288 1991
5
Genetic characteristics of the HeLa cell. 61 56
1246620 1976
6
Cell culture forensics. 56
11438719 2001
7
Short tandem repeat profiling provides an international reference standard for human cell lines. 56
11416159 2001
8
East Hela and West Hela, in memory of Stella Mamaeva, 1939-1995. 56
8964054 1996
9
Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome II. 56
2577469 1989
10
Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. 56
2881780 1986
11
Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. 56
2877730 1986
12
Suppression of tumorigenicity in somatic cell hybrids. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intraspecies hybrids of normal diploid x malignant cells. 56
3956263 1986
13
Suppression of tumorigenicity. 56
7140370 1982
14
Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. 56
7323948 1981
15
Cross-contamination of cells in culture. 56
6451928 1981
16
Characteristics of HeLa strains: permanent vs. variable features. 56
7002488 1980
17
Suppression of tumorigenicity in somatic cell hybrids. I. Suppression and reexpression of tumorigenicity in diploid human X D98AH2 hybrids and independent segregation of tumorigenicity from other cell phenotypes. 56
6934067 1980
18
Suppression of malignancy in human cells. 56
1264187 1976
19
HeLa cultures defined. 56
1246601 1976
20
Banded marker chromosomes as indicators of intraspecies cellular contamination. 56
4469665 1974
21
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. 56
4942173 1971
22
Apparent Hela cell contamination of human heteroploid cell lines. 56
5641128 1968
23
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. 54 61
20351093 2010
24
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. 54 61
20067769 2010
25
Constitutive HIF-1 activity in malignant melanoma. 54 61
20185296 2010
26
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 54 61
20395210 2010
27
HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. 54 61
20026098 2010
28
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 54 61
20429915 2010
29
Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. 54 61
19953094 2010
30
Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. 54 61
19935879 2009
31
Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. 54 61
19362787 2009
32
[Involvement of human papillomavirus in upper aero-digestive tracts cancers]. 54 61
19744917 2009
33
HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. 54 61
19775342 2009
34
Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. 54 61
19427027 2009
35
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. 54 61
19589137 2009
36
Antitumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA in malignant melanoma cells. 54 61
19441892 2009
37
Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells. 54 61
19216720 2009
38
The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. 54 61
19563645 2009
39
[Inhibitive effect of E1A gene on the cell growth of human cervical carcinoma cell in vitro]. 54 61
19483289 2009
40
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. 54 61
19202550 2009
41
Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. 54 61
19476635 2009
42
The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. 54 61
18716870 2009
43
Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. 54 61
19327639 2009
44
Differential tissue-specific protein markers of vaginal carcinoma. 54 61
19367286 2009
45
No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population. 54 61
19263211 2009
46
Immunohistochemical studies of trophoblastic tumors. 54 61
19145204 2009
47
Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. 54 61
19251084 2009
48
Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma. 54 61
19331227 2009
49
Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. 54 61
19100258 2009
50
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. 54 61
19148475 2009
51
Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. 54 61
19597291 2009
52
[Comparison of efficacy of combined use of liquid cytology and immunohistochemical assay of p16ink4 and standard procedure and high risk evaluation by polymerase chain reaction of human papillomavirus infection in diagnosing cervical dysplasia and carcinoma]. 54 61
19514374 2009
53
Status of p16(INK4a) and E-cadherin gene promoter methylation in Moroccan patients with cervical carcinoma. 54 61
20112504 2009
54
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. 54 61
18809672 2008
55
[Effects of green tea extract on expression of human papillomavirus type 16 oncoproteins-induced hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human cervical carcinoma cells]. 54 61
19080502 2008
56
A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. 54 61
18855573 2008
57
Immunohistochemical overexpression of p16 protein associated with cervical cancer in Thailand. 54 61
19256750 2008
58
p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia. 54 61
19145674 2008
59
[Effect of metastasis suppressor gene KAI1 on the proliferation and invasive ability of cervical carcinoma cells]. 54 61
19024306 2008
60
[Promoter methylation of DAPK gene in cervical carcinoma]. 54 61
18799028 2008
61
Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. 54 61
18608185 2008
62
Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas. 54 61
18494825 2008
63
Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. 54 61
18676743 2008
64
Role of 5'-CpG island hypermethylation of the FHIT gene in cervical carcinoma. 54 61
19471558 2008
65
High levels of granzyme B expression in invasive cervical carcinoma correlates to poor response to treatment. 54 61
18568772 2008
66
[Interference of HIF-1alpha by RNA reduces the expression of matrix metalloproteinase-2 in human cervical carcinoma HeLa cells]. 54 61
18570733 2008
67
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]. 54 61
18479604 2008
68
[Expression of metastasis suppressor gene KAI1 in cervical carcinoma and infections of HPV16 E6, E7 and HPV18 E6/E7]. 54 61
18575327 2008
69
The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. 54 61
18259943 2008
70
[Expression of aquaporin-8 and bcl-2 protein in human cervical carcinoma and their correlations]. 54 61
18788571 2008
71
p16(INK4a) translation suppressed by miR-24. 54 61
18365017 2008
72
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. 54 61
17622526 2008
73
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. 54 61
18055005 2008
74
Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery. 54 61
18439073 2008
75
RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. 54 61
17967866 2008
76
Nucleolin binds specifically to an AP-1 DNA sequence and represses AP1-dependent transactivation of the matrix metalloproteinase-13 gene. 54 61
17626252 2008
77
Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. 54 61
18094523 2007
78
Overexpressed active Notch1 induces cell growth arrest of HeLa cervical carcinoma cells. 54 61
17425682 2007
79
High-level inducible Smad4-reexpression in the cervical cancer cell line C4-II is associated with a gene expression profile that predicts a preferential role of Smad4 in extracellular matrix composition. 54 61
17997817 2007
80
[Expression of epidermal growth factor receptor and the correlation with HPV16/18 infection in cervical intraepithelial neoplasia and cervical carcinoma]. 54 61
18396688 2007
81
Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas. 54 61
17420726 2007
82
Transcriptional expression of survivin and its splice variants in cervical carcinomas. 54 61
17877643 2007
83
The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. 54 61
17712228 2007
84
Role of p53 in antioxidant defense of HPV-positive cervical carcinoma cells following H2O2 exposure. 54 61
17567683 2007
85
[Relationship between RAR-beta gene expression defect and its methylation]. 54 61
17961338 2007
86
Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma HepG2 cells through activation of caspase-3. 54 61
17549366 2007
87
VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro. 54 61
17549374 2007
88
Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines. 54 61
17452420 2007
89
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. 54 61
17581404 2007
90
[Clinical significance of detection of tumor suppressor genes aberrant methylation in cervical carcinoma tissue]. 54 61
17697601 2007
91
Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. 54 61
17382375 2007
92
Genetic variation of antigen processing machinery components and association with cervical carcinoma. 54 61
17366619 2007
93
Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. 54 61
17467965 2007
94
Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells. 54 61
17541155 2007
95
Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes. 54 61
17290384 2007
96
The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. 54 61
17521451 2007
97
Genetic redundancy in human cervical carcinoma cells: identification of cells with "normal" properties. 54 61
17266037 2007
98
[Expression and significance of P16INK4A and PTEN in high-risk human papillomavirus-related cervical cancer]. 54 61
17672936 2007
99
The nonsynonymous single nucleotide polymorphisms of DNA repair gene XRCC1 and susceptibility to the development of cervical carcinoma and high-risk human papillomavirus infection. 54 61
17504380 2007
100
Interference with energy metabolism by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1. 54 61
17212587 2007
101
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. 54 61
17685229 2007
102
Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms. 54 61
17079005 2007
103
RNAi knockdown of caspase-activated DNase inhibits rotenone-induced DNA fragmentation in HeLa cells. 54 61
17239993 2007
104
[Combinatorial effects of ST6Gal I siRNA and antisense oligonucleotide-mediated gene silence on metastasis ability of cervical carcinoma cells]. 54 61
17441333 2007
105
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. 54 61
17214747 2007
106
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. 54 61
16960658 2007
107
Correlation of DNA mismatch repair protein hMSH2 immunohistochemistry with p53 and apoptosis in cervical carcinoma. 54 61
17352217 2007
108
The role of p53, Bcl-2 and Ki-67 in premalignant cervical lesions and cervical cancer. 54 61
17713095 2007
109
[Effects of ST6Gal I antisense oligonucleotide-mediated gene silencing on cell adhesion and invasiveness of hela cells]. 54 61
17575688 2007
110
Antisense experiments demonstrate an exon 4 minus splice variant mRNA as the basis for expression of tNOX, a cancer-specific cell surface protein. 54 61
18351130 2007
111
Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs. 54 61
17605297 2007
112
Influence of the management of cervical carcinoma on the activity of catalase and glutathione peroxidase in erythrocytes. 54 61
18179136 2007
113
p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. 54 61
17208232 2007
114
The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. 54 61
18301453 2006
115
CEACAM1 in cervical cancer and precursor lesions: association with human papillomavirus infection. 54 61
16924126 2006
116
Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening. 54 61
16494930 2006
117
High-risk human papillomavirus, tumor suppressor protein p53 and mitomycin-C in invasive squamous cell carcinoma cervix. 54 61
17192686 2006
118
Induction of apoptosis in tumor cells by three naphthoquinone esters isolated from Thai medicinal plant: Rhinacanthus nasutus KURZ. 54 61
17015953 2006
119
Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. 54 61
17167534 2006
120
The correlation between FHIT, P53 and MMR genes in human papillomavirus-associated cervical carcinoma. 54 61
17671528 2006
121
Regulation of DNA methylation on the expression of the FHIT gene contributes to cervical carcinoma cell tumorigenesis. 54 61
16865265 2006
122
Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. 54 61
16885369 2006
123
Extracellular signal-regulated protein kinase is activated in cervical intraepithelial neoplasms but inactivated in invasive cervical carcinoma. 54 61
16792545 2006
124
Anticancer activity of grape and grape skin extracts alone and combined with green tea infusions. 54 61
16129553 2006
125
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. 54 61
16818500 2006
126
Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. 54 61
16731755 2006
127
Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway. 54 61
16269171 2006
128
Parallel cyclin E and cyclin A expression in neoplastic lesions of the uterine cervix. 54 61
16538218 2006
129
Expression profiling of cyclin B1 and D1 in cervical carcinoma. 54 61
16614707 2006
130
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia. 54 61
16391859 2006
131
Cell cycle-regulated trafficking of human telomerase to telomeres. 54 61
16339074 2006
132
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]. 54 61
16677523 2006
133
Role of mitochondria and mitochondrial cytochrome c in tubeimoside I-mediated apoptosis of human cervical carcinoma HeLa cell line. 54 61
16172906 2006
134
tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS). 54 61
16444599 2006
135
Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a. 54 61
16247485 2006
136
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. 54 61
17310826 2006
137
Analysis of hypoxia-inducible factor-1alpha accumulation and cell cycle in geldanamycin-treated human cervical carcinoma cells by laser scanning cytometry. 54 61
16228978 2005
138
Involvement of human beta-defensin-2 in proliferation of transformed cells of human cervix. 54 61
16404352 2005
139
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. 54 61
16157365 2005
140
The Fos family of transcription factors and their role in tumourigenesis. 54 61
16199154 2005
141
[Association between expression of survivin and high-risk human papillomavirus infection in cervical cancer and precancerous tissues]. 54 61
16234108 2005
142
Aberrant cell cycle regulation in cervical carcinoma. 54 61
16259056 2005
143
Differential immunoscreening identifies a glycosylation variant of the epidermal growth factor receptor in ME-180 cervical carcinoma cells. 54 61
16225421 2005
144
Transcriptional expression of the genes implicated in angiogenesis and tumor invasion in cervical carcinomas. 54 61
16000214 2005
145
[Quantities of human papillomavirus 16 E6 mRNA and its relationship with expression of survivin in cervical cancer]. 54 61
16202321 2005
146
Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. 54 61
16061633 2005
147
Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. 54 61
16103077 2005
148
Transcriptional regulation of beta-defensin-2 by lipopolysaccharide in cultured human cervical carcinoma (HeLa) cells. 54 61
15985221 2005
149
[Study on the relationship between LOH and MI of FHIT gene and the development of cervical carcinoma]. 54 61
16078573 2005
150
Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. 54 61
15899779 2005
151
[Correlation between human papilloma virus infection in cervical lesions and expression of p53, p21 proteins and Ki-67]. 54 61
16026074 2005
152
Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. 54 61
15891905 2005
153
Markers of apoptosis in stage IB squamous cervical carcinoma. 54 61
15917408 2005
154
YB-1 represses AP1-dependent gene transactivation and interacts with an AP-1 DNA sequence. 54 61
15702969 2005
155
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. 54 61
16021568 2005
156
Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. 54 61
15831939 2005
157
Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases. 54 61
16033096 2005
158
Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. 54 61
15869706 2005
159
Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300. 54 61
15904468 2005
160
Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2. 54 61
15767426 2005
161
Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. 54 61
15793301 2005
162
Influence of prostaglandin A2 and 2-methoxyestradiol on Bax and Bcl-2 expression levels in cervical carcinoma cells. 54 61
15889622 2005
163
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. 54 61
15827339 2005
164
The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. 54 61
15731267 2005
165
Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence. 54 61
15706409 2005
166
Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. 54 61
15637689 2005
167
Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. 54 61
15828450 2005
168
[Methylation and aberrant expression of the p16 gene in cervical carcinoma]. 54 61
15730957 2005
169
Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix. 54 61
15857029 2005
170
Granzyme B as a prognostic marker of cervical intraepithelial neoplasia. 54 61
15755009 2005
171
Smad4 deficiency in cervical carcinoma cells. 54 61
15531914 2005
172
Apoptotic index as predictive marker for radiosensitivity of cervical carcinoma: evaluation of membrane fluidity, biochemical parameters and apoptosis after the first dose of fractionated radiotherapy to patients. 54 61
16125335 2005
173
Correlation p53 expression and human papilloma virus deoxyribonucleic acid with clinical outcome in early uterine cervical carcinoma. 54 61
16289387 2005
174
Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. 54 61
15248030 2004
175
[Relationship between the reduction of FHIT expression and the development of cervical carcinoma]. 54 61
15573771 2004
176
Targeting endothelin receptor type A in human cervical carcinoma cells. 54 61
15838364 2004
177
Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. 54 61
15476675 2004
178
Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. 54 61
15585135 2004
179
Ge-Jee-Bok-Ryung-Hwan induces apoptosis in human cervical carcinoma HeLa cells--an endoplasmic reticulum stress pathway--. 54 61
15474552 2004
180
Analysis of molecular alterations in chromosome 8 associated with the development of uterine cervical carcinoma of Indian patients. 54 61
15491757 2004
181
Expression of epidermal growth factor receptor in cervical tissue and serum in patients with cervical neoplasia. 54 61
15874875 2004
182
Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells. 54 61
15467223 2004
183
Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. 54 61
15380586 2004
184
Ectopic expression of nonliganded retinoic acid receptor beta abrogates AP-1 activity by selective degradation of c-Jun in cervical carcinoma cells. 54 61
15308638 2004
185
Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappaB activation cascade. 54 61
15378004 2004
186
E-cadherin and catenins in early squamous cervical carcinoma. 54 61
15297198 2004
187
Relation between HPV-DNA and expression of p53, bcl-2, p21WAF-1, MIB-1, HER-2/neu and DNA ploidy in early cervical carcinoma: correlation with clinical outcome. 54 61
15201979 2004
188
The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells. 54 61
15262117 2004
189
Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. 54 61
15167830 2004
190
Up-regulation of reactive oxygen species (ROS) and resistance to Fas-mediated apoptosis in the C33A cervical cancer cell line transfected with IL-18 receptor. 54 61
15202785 2004
191
Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. 54 61
15047208 2004
192
Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. 54 61
15047823 2004
193
Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. 54 61
15116093 2004
194
Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. 54 61
15047806 2004
195
Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. 54 61
14742261 2004
196
TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. 54 61
14970278 2004
197
Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. 54 61
14668544 2004
198
tNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-)-epigallocatechin-3-gallate. 54 61
15706060 2004
199
Cyclins and proliferation markers in early squamous cervical carcinoma. 54 61
14751136 2004
200
Mechanism of acetaminophen-induced apoptosis in cultured cells: roles of caspase-3, DNA fragmentation factor, and the Ca2+ and Mg2+ endonuclease DNAS1L3. 54 61
14725611 2004
201
Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-specific antigen expression in Egyptian patients with cervical carcinoma: Relationship with prognosis. 54 61
15665394 2004
202
Mutant p53 protein in the serum of patients with cervical carcinoma: correlation with the level of serum epidermal growth factor receptor and prognostic significance. 54 61
14670624 2004
203
Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. 54 61
14681700 2004
204
MRGX is a novel transcriptional regulator that exhibits activation or repression of the B-myb promoter in a cell type-dependent manner. 54 61
14506250 2003
205
P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. 54 61
14599865 2003
206
[Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract]. 54 61
14631913 2003
207
Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. 54 61
14654550 2003
208
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. 54 61
14584072 2003
209
[Expression of bcl-2, c-erbB2, and p53 protein in cervical epithelial carcinogenesis]. 54 61
14558950 2003
210
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. 54 61
14675348 2003
211
Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells. 54 61
12967482 2003
212
A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. 54 61
13678722 2003
213
Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. 54 61
12893195 2003
214
Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm. 54 61
12926053 2003
215
Alterations of the P16 gene in uterine cervical carcinoma from Indian patients. 54 61
12911724 2003
216
[Comparison and analysis of expression of c-myc and p16 in cervical carcinoma]. 54 61
12948409 2003
217
Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. 54 61
12759237 2003
218
Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. 54 61
12713987 2003
219
Homeobox gene expression and mutation in cervical carcinoma cells. 54 61
12824890 2003
220
Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. 54 61
12719705 2003
221
No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma. 54 61
12657123 2003
222
HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. 54 61
12548555 2003
223
Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral Type 1 (IFNgamma) and Type 2 (IL-4) cytokine mRNA expression. 54 61
12628838 2003
224
Suppression of TNF-alpha mediated apoptosis by EGF in TNF-alpha sensitive human cervical carcinoma cell line. 54 61
12795334 2003
225
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. 54 61
12517802 2003
226
Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. 54 61
12504622 2003
227
Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. 54 61
12687273 2003
228
Oxidative stress and tumor markers in cervical cancer patients. 54 61
14972792 2002
229
Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression. 54 61
12504567 2002
230
The Brn-3a POU family transcription factor stimulates p53 gene expression in human and mouse tumour cells. 54 61
12431761 2002
231
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. 54 61
12438219 2002
232
[Heat shock proteins and malignancies of the female genital tract]. 54 61
12476632 2002
233
Deletion of the FHIT gene in human colorectal cancer is independent of high-risk HPV infection. 54 61
12355215 2002
234
Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. 54 61
12468347 2002
235
[Specific anti-tumor effect of immune competent cell induced by HSP-70 of HeLa cells in vitro]. 54 61
12508643 2002
236
Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line. 54 61
12370827 2002
237
Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. 54 61
12208848 2002
238
Tumor dihydropyrimidine dehydrogenase activity in advanced cervical carcinoma. 54 61
12168069 2002
239
Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma. 54 61
12193111 2002
240
Tumor necrosis factor-alpha-induced accumulation of tumor suppressor protein p53 and cyclin-dependent protein kinase inhibitory protein p21 is inhibited by insulin in ME-180S cells. 54 61
12392301 2002
241
Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. 54 61
12167476 2002
242
P53 immunohistochemical expression: messages in cervical carcinogenesis. 54 61
12190289 2002
243
[Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix]. 54 61
12479097 2002
244
P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. 54 61
12144687 2002
245
Expression of apoptotic regulators and their significance in cervical cancer. 54 61
11911971 2002
246
Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation. 54 61
11827956 2002
247
Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. 54 61
11925126 2002
248
Alterations in promoter usage and expression levels of insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF-II. 54 61
11997082 2002
249
The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. 54 61
11950905 2002
250
Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. 54 61
11996883 2002
251
Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. 54 61
11925127 2002
252
[Study on expression of cell cycle-related genes in subclonal cell lines of human cervical carcinoma]. 54 61
11953088 2002
253
[Expression and clinical significance of p53 and c-erbB2 in geriatric women with cervical carcinoma]. 54 61
12451999 2002
254
Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. 54 61
11920583 2002
255
Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. 54 61
12014654 2002
256
C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. 54 61
11850819 2002
257
Software compensation improves the analysis of heterogeneous tumor samples stained for multiparameter DNA flow cytometry. 54 61
11792380 2002
258
SNU cell lines and their application for cancer research. 54 61
11890121 2002
259
Disturbance of tumor necrosis factor alpha-mediated beta interferon signaling in cervical carcinoma cells. 54 61
11739693 2002
260
Bcl-2 expression in preinvasive and invasive cervical lesions. 54 61
12440815 2002
261
Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. 54 61
11803460 2002
262
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. 54 61
11713591 2001
263
KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma. 54 61
11696423 2001
264
CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells. 54 61
11606076 2001
265
Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. 54 61
11673561 2001
266
Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. 54 61
11745435 2001
267
Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix. 54 61
11606099 2001
268
Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. 54 61
11595134 2001
269
Soluble interleukin-6 receptor activates the human papillomavirus type 18 long control region in SW756 cervical carcinoma cells in a STAT3-dependent manner. 54 61
11562527 2001
270
Higher incidence of p53 mutation in cervical carcinomas with intermediate-risk HPV infection. 54 61
11574134 2001
271
[A novel antiapoptosis gene, survivin, bcl-2, p53 expression in cervical carcinomas]. 54 61
11769670 2001
272
Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. 54 61
11448914 2001
273
Imaging of whole tumor cut sections using a novel scanning beam confocal fluorescence MACROscope. 54 61
11516323 2001
274
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. 54 61
11466624 2001
275
Prognostic value of nm23 expression in stage IB1 cervical carcinoma. 54 61
11518746 2001
276
Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. 54 61
11529662 2001
277
Low frequency of p53 mutations in cervical carcinomas among Brazilian women. 54 61
11378660 2001
278
Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. 54 61
11378340 2001
279
Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. 54 61
11389064 2001
280
Cervical dysplasia, ploidy, and human papillomavirus status correlate with loss of Fhit expression. 54 61
11350899 2001
281
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. 54 61
11344234 2001
282
Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. 54 61
11381365 2001
283
Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. 54 61
11311493 2001
284
Quinacrine induces cytochrome c-dependent apoptotic signaling in human cervical carcinoma cells. 54 61
11339632 2001
285
Oncoprotein c-erbB-2 in squamous cell carcinoma of the uterine cervix and evaluation of its significance in response of disease to treatment. 54 61
11480225 2001
286
The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. 54 61
11108719 2001
287
Polymorphism of the WAF1 gene is related to susceptibility to cervical cancer in Japanese women. 54 61
11179504 2001
288
Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells. 54 61
11275979 2001
289
Cyclooxygenase-2 is overexpressed in human cervical cancer. 54 61
11234900 2001
290
E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma. 54 61
11161853 2001
291
Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells. 54 61
11161855 2001
292
A novel mutation lacking the bromodomain of the transcriptional coactivator p300 in the SiHa cervical carcinoma cell line. 54 61
11181085 2001
293
Overexpression of placental tissue protein 17b/TIP47 in cervical dysplasias and cervical carcinoma. 54 61
11299819 2001
294
Clinical value of thymidine kinase in patients with cervical carcinoma. 54 61
11474248 2001
295
A novel 16-kilodalton cellular protein physically interacts with and antagonizes the functional activity of c-myc promoter-binding protein 1. 54 61
11134351 2001
296
The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. 54 61
11148563 2001
297
CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. 54 61
11136572 2001
298
Requirement for ERK activation in cisplatin-induced apoptosis. 54 61
10993883 2000
299
Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. 54 61
11156231 2000
300
Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells. 54 61
11092985 2000
301
Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. 54 61
11114733 2000
302
Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells. 54 61
11131151 2000
303
Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. 54 61
11053249 2000
304
E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression. 54 61
10982822 2000
305
[Expression of PCNA antigen in cellular proliferative activity of cervical carcinoma]. 54 61
11082996 2000
306
Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production. 54 61
10925276 2000
307
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced c-Jun N-terminal kinase (JNK) phosphatase renders immortalized or transformed epithelial cells refractory to TPA-inducible JNK activity. 54 61
10807930 2000
308
Activation of p53 in cervical carcinoma cells by small molecules. 54 61
10900010 2000
309
Sensitization of tumor cells to fas killing through overexpression of heat-shock transcription factor 1. 54 61
10797318 2000
310
[Study on the carcinogenic mechanism of human papillomavirus typel6 E7 protein in cervical carcinoma]. 54 61
11503038 2000
311
Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. 54 61
10836996 2000
312
Expression of cyclin E and p27(KIP1) in cervical carcinoma. 54 61
10779628 2000
313
BAG-1 promotes apoptosis induced by N-(4-hydroxyphenyl)retinamide in human cervical carcinoma cells. 54 61
10772821 2000
314
Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. 54 61
10813720 2000
315
Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7. 54 61
10817508 2000
316
The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. 54 61
10739702 2000
317
The effects of interferon on the expression of human papillomavirus oncogenes. 54 61
10675406 2000
318
p53 status and human papillomavirus infection in Thai women with cervical carcinoma. 54 61
11023067 2000
319
Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. 54 61
10675384 2000
320
p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women. 54 61
10719811 2000
321
Influence of the G2 cell cycle block abrogator pentoxifylline on the expression and subcellular location of cyclin B1 and p34cdc2 in HeLa cervical carcinoma cells. 54 61
10741643 2000
322
Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. 54 61
10652435 2000
323
[The inhibitory effect of bcl-2 antisense oligodeoxynucleotide/RNA on the growth of cervical carcinoma in vitro]. 54 61
11809111 2000
324
Type of human papillomavirus and expression of p53 in elderly women with cervical cancer. 54 61
10729761 2000
325
FHIT alterations in cancerous and non-cancerous cervical epithelium. 54 61
10585575 2000
326
Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. 54 61
10644993 2000
327
EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. 54 61
10656450 2000
328
Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. 54 61
10618615 2000
329
Overexpression of Bcl-2 partly inhibits apoptosis of human cervical cancer SiHa cells induced by arsenic trioxide. 54 61
11775218 2000
330
Mutation and transcription analyses of the p63 gene in cervical carcinoma. 54 61
10568821 1999
331
Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. 54 61
10567656 1999
332
Hepatitis C virus core protein does not inhibit apoptosis in human hepatoma cells. 54 61
10583438 1999
333
Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma. 54 61
10571523 1999
334
Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. 54 61
10597238 1999
335
Is placental tissue protein 17b/TIP47 a new factor in cervical cancer genesis? 54 61
10697545 1999
336
In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. 54 61
10535995 1999
337
Different profiles of allelic losses in cervical carcinoma cases in Surinam and The Netherlands. 54 61
10491526 1999
338
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. 54 61
10446984 1999
339
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein. 54 61
10393912 1999
340
Transient increases of apoptosis and Bax expression occurring during radiotherapy in patients with invasive cervical carcinoma. 54 61
10391567 1999
341
Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein. 54 61
10392903 1999
342
The significance of Erb-b2 immunostaining in cervical cancer. 54 61
10366459 1999
343
MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. 54 61
10366463 1999
344
Correlation between EGFR and c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in cervical carcinoma. 54 61
10412330 1999
345
Significant increase of a specific variant TSG101 transcript during the progression of cervical neoplasia. 54 61
10505033 1999
346
Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. 54 61
10329038 1999
347
The mechanism of retinoic acid radiosensitization is independent of AP-1 repression in a cervical carcinoma cell line. 54 61
10329043 1999
348
Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma. 54 61
10223242 1999
349
Human SWI-SNF component BRG1 represses transcription of the c-fos gene. 54 61
10082538 1999
350
The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix. 54 61
10094882 1999
351
Functional domains of c-myc promoter binding protein 1 involved in transcriptional repression and cell growth regulation. 54 61
10082554 1999
352
Proliferative activity in cervical intraepithelial neoplasia and cervical carcinoma. 54 61
11593543 1999
353
Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. 54 61
10098746 1999
354
Elderly Japanese women with cervical carcinoma show higher proportions of both intermediate-risk human papillomavirus types and p53 mutations. 54 61
10098748 1999
355
Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers. 54 61
10027311 1999
356
Overexpression of anti-apoptotic gene BAG-1 in human cervical cancer. 54 61
10047462 1999
357
A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. 54 61
10027335 1999
358
p53 immunohistochemical expression of Egyptian cervical carcinoma. 54 61
10607922 1999
359
bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. 54 61
10037278 1999
360
Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. 54 61
9885382 1999
361
Differential expression of keratins 10, 17, and 19 in normal cervical epithelium, cervical intraepithelial neoplasia, and cervical carcinoma. 54 61
10343611 1999
362
Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. 54 61
9891436 1998
363
Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha. 54 61
9829842 1998
364
Up-regulation of p53 by antisense expression of HPV18 E6 oncogene does not influence the level of MN/CA IX tumor-associated protein in HeLa cervical carcinoma cells. 54 61
9772303 1998
365
Establishment and characterization of a new HPV-negative squamous cell carcinoma cell line (Yumoto) from the human uterine cervix. 54 61
9790785 1998
366
The prognostic significance of beta human chorionic gonadotrophin and its metabolites in women with cervical carcinoma. 54 61
9930074 1998
367
Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. 54 61
9824053 1998
368
Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. 54 61
9790789 1998
369
PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. 54 61
9672853 1998
370
Bax protein expression correlates with radiation-induced apoptosis in radiation therapy for cervical carcinoma. 54 61
9655299 1998
371
[Bax and Bcl-2 expression predict response to radiotherapy in human cervical cancer]. 54 61
9703806 1998
372
Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. 54 61
9698478 1998
373
Transforming growth factor-beta 1 induces apoptosis through down-regulation of c-myc gene and overexpression of p27Kip1 protein in cervical carcinoma. 54 61
9648593 1998
374
Expression of heat shock protein 70 and c-myc in cervical carcinoma. 54 61
9673366 1998
375
Analysis of FHIT transcripts in cervical and endometrial cancers. 54 61
9537583 1998
376
Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. 54 61
9524287 1998
377
nm23 expression in carcinoma of the uterine cervix. 54 61
9641240 1998
378
Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. 54 61
9465813 1998
379
Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. 54 61
9808425 1998
380
Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. 54 61
10338155 1998
381
Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix. 54 61
9817979 1998
382
Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index. 54 61
9568185 1998
383
[Relationship between nm23-H1 expression and lymph node metastasis and prognosis in cervical cancer]. 54 61
9772433 1997
384
[Relationship between human papillomavirus E7 protein and Rb gene product in fresh tissues of squamous cervical carcinoma]. 54 61
9772434 1997
385
[Overexpression of p53 protein and its relation to HPV in squamous intraepithelial lesion and cervical carcinoma]. 54 61
10374328 1997
386
Reduced gene expression of E-cadherin and associated catenins in human cervical carcinoma cell lines. 54 61
9461036 1997
387
Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. 54 61
9358772 1997
388
Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. 54 61
9354423 1997
389
Relationship between human papillomavirus infection and overexpression of p53 protein in cervical carcinomas and lymph node metastases. 54 61
9334921 1997
390
The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. 54 61
9470836 1997
391
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. 54 61
9293917 1997
392
[Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma]. 54 61
15617346 1997
393
Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. 54 61
9274913 1997
394
Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. 54 61
9242443 1997
395
[Mutation and expression of p53 gene in nasopharyngeal carcinoma, cervical carcinoma and lung cancer]. 54 61
10072870 1997
396
Genomic deletion and p53 inactivation in cervical carcinoma. 54 61
9219832 1997
397
Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. 54 61
9233761 1997
398
The role of inhibitory phosphorylation of CDC2 following DNA replication block and radiation-induced damage in human cells. 54 61
9201712 1997
399
Dispersed and aggregated gap junction channels identified by immunogold labeling of freeze-fractured membranes. 54 61
9194487 1997
400
The additive antiproliferative effect of all-trans retinoic acid and interferon-alpha2a on human cervical carcinoma cell lines is not associated with increased expression of retinoid receptors. 54 61
9215617 1997
401
In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. 54 61
9185711 1997
402
The effects of vinblastine on the expression of human immunodeficiency virus type 1 long terminal repeat. 54 61
9225075 1997
403
p16INK4 and p15INK4B alterations in primary gynecologic malignancy. 54 61
9159345 1997
404
Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids. 54 61
9135068 1997
405
High-level expression of the retinoic acid receptor beta gene in normal cells of the uterine cervix is regulated by the retinoic acid receptor alpha and is abnormally down-regulated in cervical carcinoma cells. 54 61
9108446 1997
406
c-Myb trans-activates the human DNA topoisomerase IIalpha gene promoter. 54 61
9045645 1997
407
Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix. 54 61
9059353 1997
408
Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. 54 61
9166931 1997
409
Human papillomavirus infection and TP53 gene mutation in primary cervical carcinoma. 54 61
9208900 1997
410
Inhibitory effects of ubenimex (bestatin) on the invasion of uterine cervical carcinoma cells and their production and activation of gelatinase A. 54 61
9355022 1997
411
p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. 54 61
8806692 1996
412
Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. 54 61
8920796 1996
413
Different ligand responsiveness of human retinoic-acid-receptor beta-gene transcription in tumorigenic and non-tumorigenic cervical-carcinoma-derived cell lines is mediated through a large retinoic-acid-response domain. 54 61
8707417 1996
414
Effect of radiotherapy and chemoradiotherapy on circulating antioxidant system of human uterine cervical carcinoma. 54 61
8791280 1996
415
The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. 54 61
9162297 1996
416
BCL-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma. 54 61
8691340 1996
417
Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. 54 61
8620490 1996
418
Presence of oncogenic HPV DNAs in cervical carcinoma tissues and pelvic lymph nodes associating with proliferating cell nuclear antigen expression. 54 61
8774650 1996
419
Expression of epidermal growth factor receptor in carcinoma of the cervix. 54 61
8631552 1996
420
Growth suppression of a cervical cancer cell line (TMCC-1) by the human wild-type p53 gene. 54 61
8631546 1996
421
Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells. 54 61
7503188 1995
422
[Human papillomavirus, human cytomegalovirus and p53 gene in cervical carcinoma]. 54 61
8745488 1995
423
Modulation of expression of p53 and cell proliferation in locally advanced cervical carcinoma after neoadjuvant combination chemotherapy. 54 61
8674562 1995
424
Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice. 54 61
7641187 1995
425
Induction of cell death in murine fibroblasts by a c-myc promoter binding protein. 54 61
8519685 1995
426
Epidermal growth factor induction of human papillomavirus type 16 E6/E7 MRNA in tumor cells involves two AP-1 binding sites in the viral enhancer. 54 61
7636475 1995
427
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. 54 61
7640226 1995
428
p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. 54 61
8630877 1995
429
[Detection of p53 mutation using PCR-SSCP silver staining method]. 54 61
8706159 1995
430
Keratinocyte growth factor is a bifunctional regulator of HPV16 DNA-immortalized cervical epithelial cells. 54 61
7730415 1995
431
Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. 54 61
7736397 1995
432
p53 and human papilloma virus type 16 in cervical intraepithelial neoplasia and carcinoma. 54 61
8601524 1995
433
Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. 54 61
7768985 1995
434
Cathepsin B in predicting the extent of the cervix carcinoma. 54 61
7617069 1995
435
The relationship between proliferating cell nuclear antigen (PCNA), nuclear DNA content and mutant p53 during genesis of cervical carcinoma. 54 61
7718254 1995
436
Enhancer function of a 53-bp repetitive element in the 5' flanking region of the human neutrophil elastase gene. 54 61
7945385 1994
437
Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. 54 61
7516819 1994
438
Regulation of transcription from the human muscle phosphofructokinase P2 promoter by the Sp1 transcription factor. 54 61
8024691 1994
439
p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status. 54 61
8142262 1994
440
[Analysis of p53 gene in gynecologic tumors]. 54 61
8152158 1994
441
p53 mutations in HPV-negative cervical carcinoma. 54 61
8302581 1994
442
Integration site of human papillomavirus type-18 DNA in chromosome band 8q22.1 of C4-I cervical carcinoma: DNase I hypersensitivity and methylation of cellular flanking sequences. 54 61
7507697 1994
443
p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. 54 61
8238255 1993
444
Human papillomavirus 16 immortalization of normal human ectocervical epithelial cells alters retinoic acid regulation of cell growth and epidermal growth factor receptor expression. 54 61
8402622 1993
445
Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. 54 61
8397367 1993
446
Mutations of p53 and human papillomavirus infection in cervical carcinoma. 54 61
8393371 1993
447
Reversal of an interferon-gamma-resistant phenotype by poly(I:C): possible role of double-stranded RNA-activated kinase in interferon-gamma signaling. 54 61
7901291 1993
448
Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. 54 61
8392752 1993
449
Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. 54 61
8319904 1993
450
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. 54 61
8388491 1993
451
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. 54 61
8387205 1993
452
Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas. 54 61
8384745 1993
453
The Sp1 transcription factor binds the CD11b promoter specifically in myeloid cells in vivo and is essential for myeloid-specific promoter activity. 54 61
8096519 1993
454
Characterization of cis-acting elements and transacting factors involved in the tissue-specific and developmental regulation of IGFBP-1 gene expression. 54 61
7683517 1993
455
Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. 54 61
8459036 1993
456
Expression of keratins 1, 6, 15, 16, and 20 in normal cervical epithelium, squamous metaplasia, cervical intraepithelial neoplasia, and cervical carcinoma. 54 61
7679549 1993
457
Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines. 54 61
8380785 1993
458
Multiple fractions of gamma rays do not induce overexpression of c-myc or c-Ki-ras oncogenes in human cervical carcinoma cells. 54 61
8289968 1993
459
Presence of p53 mutation in human cervical carcinomas associated with HPV-33 infection. 54 61
1363512 1992
460
Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. 54 61
1327506 1992
461
Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. 54 61
1380890 1992
462
The upstream region of the mouse N-myc gene: identification of an enhancer element that functions preferentially in neuroblastoma IMR32 cells. 54 61
1327147 1992
463
Total inhibition of involucrin synthesis by a novel two-step antisense procedure. Further examination of the relationship between differentiation and malignancy in hybrid cells. 54 61
1385457 1992
464
Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. 54 61
1355495 1992
465
Loss of heterozygosity on chromosome 17p and mutant p53 in HPV-negative cervical carcinomas. 54 61
1352566 1992
466
Identification of epidermal growth factor Thr-669 phosphorylation site peptide kinases as distinct MAP kinases and p34cdc2. 54 61
1320411 1992
467
[Molecular biological study on the overexpression of c-myc gene in uterine cervical carcinomas]. 54 61
1619315 1992
468
Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. 54 61
1316611 1992
469
Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. 54 61
1322242 1992
470
Specific N-methylations of HPV-16 E7 peptides alter binding to the retinoblastoma suppressor protein. 54 61
1309779 1992
471
Newly established uterine cervical carcinoma cell line with co-amplification of human papillomavirus DNA and c-myc gene. 54 61
1721614 1991
472
The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. 54 61
1648218 1991
473
p53 point mutation in HPV negative human cervical carcinoma cell lines. 54 61
1646990 1991
474
Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. 54 61
1648361 1991
475
Characterization of rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues. 54 61
1985917 1991
476
Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. 54 61
1668886 1991
477
A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology. 54 61
2379509 1990
478
Immunohistochemical investigation and northern blot analysis of c-erB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. 54 61
1980167 1990
479
3-(3-Methoxyphenyl)-6-(3-amino-4-methoxyphenyl)-7H-[1,2,4] triazolo [3,4-b][1,3,4] thiadiazine, a novel tubulin inhibitor, evokes G2/M cell cycle arrest and apoptosis in SGC-7901 and HeLa cells. 61
31642107 2020
480
Diaporone A, a new antibacterial secondary metabolite from the plant endophytic fungus Diaporthe sp. 61
31666659 2020
481
Insertional oncogenesis by HPV70 revealed by multiple genomic analyses in a clinically HPV-negative cervical cancer. 61
31407403 2020
482
Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review. 61
31802228 2020
483
Screening for sexual health concerns in survivors of gynecological cancer. 61
31104133 2020
484
Pulmonary recurrence after radical hysterectomy for uterine cervical carcinoma. 61
32027187 2020
485
Tissue-based metabolomics reveals potential biomarkers for cervical carcinoma and HPV infection. 61
31465717 2020
486
FDG-PET/CT identifies predictors of survival in patients with locally advanced cervical carcinoma and para-aortic lymph node involvement to increase treatment. 61
32034109 2020
487
Folate inhibits miR-27a-3p expression during cervical carcinoma progression and oncogenic activity in human cervical cancer cells. 61
31918266 2020
488
Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. 61
31918996 2020
489
Nucleoporin 107 Promotes the Survival of Tumor Cells in Cervical Cancers. 61
31487736 2020
490
Evaluation of the Burden of HPV-Related Hospitalizations as a Useful Tool to Increase Awareness: 2007-2017 Data from the Sicilian Hospital Discharge Records. 61
31991909 2020
491
Laparoendoscopic Single-site Radical Hysterectomy with Vaginal Closure and Without Uterine Manipulator for FIGO IB1 Cervical Cancer. 61
31926301 2020
492
LncRNA SNHG8 accelerates proliferation and inhibits apoptosis in HPV-induced cervical cancer through recruiting EZH2 to epigenetically silence RECK expression. 61
31961005 2020
493
Disparities in the Use of Adjuvant External Beam Radiation Therapy in Node-positive Cervical Cancer Patients Following Hysterectomy. 61
31633516 2020
494
Structural, spectral characterization and molecular docking analyses of mer-ruthenium (II) complexes containing the bidentate chelating ligands. 61
31344575 2020
495
Deregulation of H19 is associated with cervical carcinoma. 61
31229557 2020
496
Relevance of routine pathology review in cervical carcinoma. 61
31919628 2020
497
MicroRNA-769-5p suppresses cell growth and migration via targeting NUSAP1 in bladder cancer. 61
31901150 2020
498
Noninvasive CT radiomic model for preoperative prediction of lymph node metastasis in early cervical carcinoma. 61
31957473 2020
499
Factors in the feasibility and safety of outpatient robotic-assisted hysterectomy for endometrial or cervical carcinoma. 61
32008793 2020
500
Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy. 61
31753388 2020
501
The role of programmed cell death ligand-1/ programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy. 61
32003657 2020
502
Correction: Zhao, X.W., et al. Dioscin Induces the Apoptosis of Human Cervical Carcinoma HeLa and SiHa Cells Through ROS-mediated DNA Damage, Cell Cycle Arrest and Mitochondrial Signaling Pathways. Molecules 2016, 21, 730. 61
31935956 2020
503
Photodynamic therapy in 2D and 3D human cervical carcinoma cell cultures employing LED light sources emitting at different wavelengths. 61
31739296 2020
504
Long non-coding RNA RP11-480I12.5 promotes cervical carcinoma progression by regulating the Wnt/β-catenin signaling pathway. 61
31897160 2020
505
Lymph Node Ratio Can Better Predict Prognosis than Absolute Number of Positive Lymph Nodes in Operable Cervical Carcinoma. 61
31935729 2020
506
The value of DWI in predicting the response to synchronous radiochemotherapy for advanced cervical carcinoma: comparison among three mathematical models. 61
31937371 2020
507
Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma: An updated meta-analysis based on randomized controlled trials. 61
31895831 2020
508
Ferulic Acid Induces Apoptosis of HeLa and Caski Cervical Carcinoma Cells by Down-Regulating the Phosphatidylinositol 3-Kinase (PI3K)/Akt Signaling Pathway. 61
31983729 2020
509
Polyethyleneimine coated Fe3O4 magnetic nanoparticles induce autophagy, NF-κB and TGF-β signaling pathway activation in HeLa cervical carcinoma cells via reactive oxygen species generation. 61
31664285 2020
510
Comparison of Organosulfur and Amino Acid Composition between Triploid Onion Allium cornutum Clementi ex Visiani, 1842, and Common Onion Allium cepa L., and Evidences for Antiproliferative Activity of Their Extracts. 61
31941040 2020
511
Human papillomavirus and abnormal cervical lesions among HIV-infected women in HIV-discordant couples from Kenya. 61
31919275 2020
512
Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. 61
31492932 2020
513
Iridium(III) coordination of N(6) modified adenine derivatives with aminoacid chains. 61
31982811 2020
514
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. 61
31948126 2020
515
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). 61
31924334 2020
516
The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy. 61
31788991 2020
517
Chamuangone from Garcinia cowa leaves inhibits cell proliferation and migration and induces cell apoptosis in human cervical cancer in vitro. 61
31875979 2019
518
A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab. 61
31818277 2019
519
Carboplatin Use in Pregnancy for Stage IB3 Cervical Cancer: Case Report and Review of the Literature. 61
31794686 2019
520
Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer. 61
31696367 2019
521
ROS-Mediated Apoptosis and Anticancer Effect Achieved by Artesunate and Auxiliary Fe(II) Released from Ferriferous Oxide-Containing Recombinant Apoferritin. 61
31701665 2019
522
Long non-coding RNA MIR205HG regulates KRT17 and tumor processes in cervical cancer via interaction with SRSF1. 61
31655037 2019
523
Silencing long noncoding RNA OGFRP1 inhibits the proliferation and migration of cervical carcinoma cells. 61
31512281 2019
524
Baicalein blocked cervical carcinoma cell proliferation by targeting CCND1 via Wnt/β-catenin signaling pathway. 61
31284780 2019
525
[Development of Decision Aids for Organized Cervical Carcinoma Screening in Germany]. 61
31830768 2019
526
MiR-195-5p inhibits the cell migration and invasion of cervical carcinoma through suppressing ARL2. 61
31858533 2019
527
Strong in vitro and vivo cytotoxicity of novel organoplatinum(II) complexes with quinoline-coumarin derivatives. 61
31593828 2019
528
Anti-cancer activity of Conyza blinii saponin against cervical carcinoma through MAPK/TGF-β/Nrf2 signaling pathways. 61
31891798 2019
529
Pelvic side wall recurrence in locally advanced cervical carcinoma treated with definitive chemoradiation-clinical impact of pelvic wall dose. 61
31322915 2019
530
Chemopreventive Effect of β-Cryptoxanthin on Human Cervical Carcinoma (HeLa) Cells Is Modulated through Oxidative Stress-Induced Apoptosis. 61
31892217 2019
531
Cardiac Glycoside Compound Isolated from Helleborus thibetanus Franch Displays Potent Toxicity against HeLa Cervical Carcinoma Cells through ROS-Independent Autophagy. 61
31714069 2019
532
Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells. 61
30963795 2019
533
Single-Center Study of Lymphoepithelioma-Like Carcinoma of Uterine Cervix over a 10-Year Period. 61
31835382 2019
534
Analysis of Alpina officinarum Hance, chemically and biologically. 61
31885470 2019
535
Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer. 61
31485631 2019
536
Tryptoline-based benzothiazoles re-sensitize MRSA to β-lactam antibiotics. 61
31521461 2019
537
[A Case of Synchronous and Solitary Gallbladder Metastasis from Gastric Cancer]. 61
31748489 2019
538
[HPV vaccination: not only female adolescents and not only prophylactic. Review and position paper of the Italian HPV Study Group (IHSG)]. 61
31741364 2019
539
Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates. 61
31102568 2019
540
NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling. 61
31526565 2019
541
Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas. 61
31766658 2019
542
Knockdown of lncRNA CCEPR suppresses colorectal cancer progression. 61
31602230 2019
543
[The 2019 FIGO classification for cervical carcinoma-what's new?] 61
31612260 2019
544
Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. 61
31302345 2019
545
Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? 61
31867430 2019
546
Coix lacryma-jobi var. ma-yuen Stapf sprout extract induces cell cycle arrest and apoptosis in human cervical carcinoma cells. 61
31729992 2019
547
Minimally Invasive Surgery for Early-Stage Cervical Carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results. 61
31560582 2019
548
Gold-Hybridized Zinc Oxide Nanorods as Real-Time Low-Cost NanoBiosensors for Detection of virulent DNA signature of HPV-16 in Cervical Carcinoma. 61
31745139 2019
549
LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer. 61
31499118 2019
550
Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells. 61
31436299 2019
551
Singlet oxygen photo-production by perylene bisimide derivative Langmuir-Schaefer films for photodynamic therapy applications. 61
31228753 2019
552
Iliac Insufficiency Fracture: "Bow Sign" on Bone Scan. 61
31579212 2019
553
Adenoid basal carcinoma combined with invasive squamous cell carcinoma of uterine cervix: A case report of a 37-year-old woman and literature review. 61
31211485 2019
554
HIV status does not have an impact on positron emission tomography-computed tomography (PET-CT) findings or radiotherapy treatment recommendations in patients with locally advanced cervical cancer. 61
31413068 2019
555
Papillary squamotransitional cell carcinoma of the uterine cervix: a case report and review of the literature. 61
31655625 2019
556
Two-Photon Fluorescent Nanoprobe for Glutathione Sensing and Imaging in Living Cells and Zebrafish Using a Semiconducting Polymer Dots Hybrid with Dopamine and β-Cyclodextrin. 61
31480840 2019
557
A natural product enhances apoptosis via mitochondria/caspase-mediated pathway in HeLa cells. 61
31099051 2019
558
Synthesis and Evaluation of Anticancer Activity of New 4-Acyloxy Derivatives of Robustic Acid. 61
31717797 2019
559
Skin metastasis from squamous cell carcinoma of the cervix to the lower extremities: Case report and review of the literature. 61
31742189 2019
560
Prognostic value of lymphovascular space invasion in patients with early stage cervical cancer in Jilin, China: A retrospective study. 61
31577720 2019
561
Prevalence of human papillomavirus type 16 in Sudanese women diagnosed with cervical carcinoma. 61
31898666 2019
562
Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma. 61
31464522 2019
563
The added benefit of transvaginal sonography in the clinical staging of cervical carcinoma. 61
31628851 2019
564
TP53 mediated miR-3647-5p prevents progression of cervical carcinoma by targeting AGR2. 61
31436390 2019
565
BAX is an essential key mediator of AP5M1-induced apoptosis in cervical carcinoma cells. 61
31427081 2019
566
IGF2 is Deregulated During the Development of Uterine Cervical Carcinoma in Indian Patients. 61
30949792 2019
567
One-Step Facile Synthesis of Nitrogen-Doped Carbon Dots: A Ratiometric Fluorescent Probe for Evaluation of Acetylcholinesterase Activity and Detection of Organophosphorus Pesticides in Tap Water and Food. 61
31532667 2019
568
Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development. 61
31375269 2019
569
Assessment of parametrial invasion of cervical carcinoma, the role of T2-weighted MRI and diffusion weighted imaging with or without fusion. 61
31383355 2019
570
Analysis of the risk factors of residual lesions after conization and prognosis of multifocal micro-invasive squamous cell cervical carcinoma treated with different types of surgery. 61
31475064 2019
571
Anticancer potential of zinc oxide nanoparticles against cervical carcinoma cells synthesized via biogenic route using aqueous extract of Gracilaria edulis. 61
31349511 2019
572
Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: Concurrent cohorts with a 5-year follow-up. 61
31583683 2019
573
Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer. 61
31696811 2019
574
Synthesis and Biological Evaluation of Structurally Diverse Benzimidazole Scaffolds as Potential Chemotherapeutic Agents. 61
31746304 2019
575
Hypomethylation of the lncRNA SOX21-AS1 has clinical prognostic value in cervical cancer. 61
31369759 2019
576
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. 61
31410178 2019
577
On Modeling Diversity in Electrical Cellular Response: Data-Driven Approach. 61
31385505 2019
578
Quantitative assessment of the association between TAP2 rs241447 polymorphism and cancer risk. 61
31074096 2019
579
Effects of carbon dots surface functionalities on cellular behaviors - Mechanistic exploration for opportunities in manipulating uptake and translocation. 61
31121381 2019
580
Human papillomavirus as an independent risk factor of invasive cervical and endometrial carcinomas in Jordan. 61
31519382 2019
581
Dihydrofolate reductase inhibition effect of 5-substituted pyrido[2,3-d]pyrimidines: Synthesis, antitumor activity and molecular modeling study. 61
31260878 2019
582
Expression of SMAD4 is Retained in Most Gynecologic Tumors with Mucinous Differentiation. 61
31569186 2019
583
Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma. 61
31403858 2019
584
Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. 61
31541073 2019
585
miR-145 Contributes to the Progression of Cervical Carcinoma by Directly Regulating FSCN1. 61
31271056 2019
586
Synthesis, characterization and cytotoxicity of alanine-capped CuS nanoparticles using human cervical carcinoma HeLa cells. 61
31185196 2019
587
Evaluation of various apparent diffusion coefficient measurement techniques in pre-operative staging of early cervical carcinoma. 61
31439228 2019
588
Systematic investigation of the antiproliferative activity of a series of ruthenium terpyridine complexes. 61
31242458 2019
589
Neoadjuvant chemotherapy does not improve the prognosis and lymph node metastasis rate of locally advanced cervical squamous cell carcinoma: A retrospective cohort study in China. 61
31574835 2019
590
Deep insights into the response of human cervical carcinoma cells to a new cyano enone-bearing triterpenoid soloxolone methyl: a transcriptome analysis. 61
31523389 2019
591
Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery. 61
31912674 2019
592
Intravoxel Incoherent Motion Combined With Dynamic Contrast-Enhanced Perfusion MRI of Early Cervical Carcinoma: Correlations Between Multimodal Parameters and HIF-1α Expression. 61
30648775 2019
593
Assessment of Antioxidant and Cytotoxic Activities of Extracts of Dendrobium crepidatum. 61
31547263 2019
594
SALL4 promotes the tumorigenicity of cervical cancer cells through activation of the Wnt/β-catenin pathway via CTNNB1. 61
31336010 2019
595
Dietary Inflammatory Index and Its Relationship with Cervical Carcinogenesis Risk in Korean Women: A Case-Control Study. 61
31382563 2019
596
Whole Lesion Histogram Analysis Derived From Morphological MRI Sequences Might be Able to Predict EGFR- and Her2-Expression in Cervical Cancer. 61
30318289 2019
597
Intratumor Heterogeneity in Interstitial Fluid Pressure in Cervical and Pancreatic Carcinoma Xenografts. 61
31174058 2019
598
Syphilitic Cervicitis with Cervical Cancer Presenting as Oropharyngeal Syphilis. 61
30996173 2019
599
Changes Over the Fermentation Period in Phenolic Compounds and Antioxidant and Anticancer Activities of Blueberries Fermented by Lactobacillus plantarum. 61
31313311 2019
600
CCEPR is a novel clinical biomarker for prognosis and regulates cell proliferation through PCNA in osteosarcoma. 61
30861164 2019
601
Prognostic value of posttreatment HPV-specific antibodies in patients with oropharyngeal tumors. 61
30986340 2019
602
Aberrantly elevated Bmi1 promotes cervical cancer tumorigenicity and tumor sphere formation via enhanced transcriptional regulation of Sox2 genes. 61
31173263 2019
603
A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation. 61
31438631 2019
604
Discovery and evaluation on the antibacterial and cytotoxic activities of a novel antifungalmycin N2 produced from Streptomyces sp. strain N2. 61
31411045 2019
605
lncRNA-CCHE1 is involved in migration and invasion but not in proliferation of pancreatic adenocarcinoma cells possibly by interacting with ROCK1. 61
31423182 2019
606
Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT. 61
31470801 2019
607
Role of GS28 in sodium nitroprusside-induced cell death in cervical carcinoma cells. 61
31066958 2019
608
Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions. 61
31208965 2019
609
Lower Genital Tract Dysplasia in Female Solid Organ Transplant Recipients. 61
31306332 2019
610
[Analysis of recurrence and its influencing factors in patients with cervical HSIL within 24 months after LEEP]. 61
31461810 2019
611
Casiopeina II‑gly acts on lncRNA MALAT1 by miR‑17‑5p to inhibit FZD2 expression via the Wnt signaling pathway during the treatment of cervical carcinoma. 61
31524268 2019
612
The supernatant of cervical carcinoma cells lines induces a decrease in phosphorylation of STAT-1 and NF-κB transcription factors associated with changes in profiles of cytokines and growth factors in macrophages derived from U937 cells. 61
31099286 2019
613
Imaging and Staging of Cervical Cancer. 61
31375168 2019
614
The Value of IVIM DWI in Combination with Conventional MRI in Identifying the Residual Tumor After Cone Biopsy for Early Cervical Carcinoma. 61
30385207 2019
615
The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study. 61
31414206 2019
616
miR-199a-5p promotes proliferation and metastasis and epithelial-mesenchymal transition through targeting PIAS3 in cervical carcinoma. 61
30937952 2019
617
Cervical carcinoma high-expressed long non-coding RNA 1 may promote growth of colon adenocarcinoma through interleukin-17A. 61
31423215 2019
618
Effects of different analgesia regimens on early post-operative cognitive dysfunction in elderly patients undergoing radical resection of cervical carcinoma. 61
31363379 2019
619
Measurement of Cervical Regression and Optimizing Brachytherapy Schedule Concurrently with External Beam Radiation Therapy in Cervical Carcinoma. 61
31588384 2019
620
Physicochemical and pathohistological changes in experimental fibrosarcoma tumors of hamsters treated with metformin and itraconazole. 61
31423237 2019
621
Polychlorinated biphenyls promote cell survival through pyruvate kinase M2-dependent glycolysis in HeLa cells. 61
30821169 2019
622
Prognostic Values of Platelet-Associated Indicators in Resectable Cervical Cancer. 61
31523206 2019
623
Curcumin ameliorates the targeted delivery of methotrexate intercalated montmorillonite clay to cancer cells. 61
31078644 2019
624
ESRP1 Induces Cervical Cancer Cell G1-Phase Arrest Via Regulating Cyclin A2 mRNA Stability. 61
31362365 2019
625
Single-molecule counting of oxidative DNA damage in telomeres from cancer cells. 61
31194209 2019
626
Novel Derivatives of Deoxycholic Acid Bearing Linear Aliphatic Diamine and Aminoalcohol Moieties and their Cyclic Analogs at the C3 Position: Synthesis and Evaluation of Their In Vitro Antitumor Potential. 61
31330911 2019
627
New Monoclonal Antibodies for a Selective Detection of Membrane-Associated and Soluble Forms of Carbonic Anhydrase IX in Human Cell Lines and Biological Samples. 61
31349673 2019
628
In Vitro Interactions of Moroccan Propolis Phytochemical's on Human Tumor Cell Lines and Anti-Inflammatory Properties. 61
31362402 2019
629
Chemical diversity and anti-proliferative activity of marine algae. 61
30253657 2019
630
Radical abdominal trachelectomy and pelvic lymphadenectomy in a nulliparous patient with cervical adenocarcinoma: A case report. 61
31193447 2019
631
The Health-Benefits and Phytochemical Profile of Salvia apiana and Salvia farinacea var. Victoria Blue Decoctions. 61
31349575 2019
632
Diffusion Kurtosis Imaging in the Assessment of Cervical Carcinoma. 61
31324577 2019
633
Innervation of cervical carcinoma is mediated by cancer-derived exosomes. 61
31003747 2019
634
KGFR and MMP9 expression are correlates with cancer growth in cervical carcinoma. 61
31317692 2019
635
Anti-cervical carcinoma effect of Portulaca oleracea L. polysaccharides by oral administration on intestinal dendritic cells. 61
31277622 2019
636
The autophagy protein ATG9A promotes HIV-1 infectivity. 61
31269971 2019
637
A study on the correlation between radiation field size and gamma index passing rate for MatriXX. 61
31348271 2019
638
Quantum Dot Based Fluorescent Traffic Light Nanoprobe for Specific Imaging of Avidin-Type Biotin Receptor and Differentiation of Cancer Cells. 61
31251580 2019
639
MicroRNA-215-3p suppresses the growth and metastasis of cervical cancer cell via targeting SOX9. 61
31298315 2019
640
The Ethanol Crude Extraction of Cyperus Rotundus Regulates Apoptosis-associated Gene Expression in HeLa Human Cervical Carcinoma Cells In Vitro. 61
31262896 2019
641
Albumin-MnO2 gated hollow mesoporous silica nanosystem for modulating tumor hypoxia and synergetic therapy of cervical carcinoma. 61
30978612 2019
642
Outcome of Combined Neoadjuvant Chemotherapy and Vitamin A in Advanced Cervical Carcinoma: A Randomized Double-Blind Clinical Trial. 61
31350987 2019
643
DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma. 61
30858145 2019
644
Synthesis of Pyrrolo[3,4-b]pyridin-5-ones via Multicomponent Reactions and In Vitro-In Silico Studies Against SiHa, HeLa, and CaSki Human Cervical Carcinoma Cell Lines. 61
31336585 2019
645
Three-dimensional reconstruction of the distribution of elemental tags in single cells using laser ablation ICP-mass spectrometry via registration approaches. 61
30790022 2019
646
Amide proton transfer imaging to evaluate the grading of squamous cell carcinoma of the cervix: A comparative study using 18 F FDG PET. 61
30430677 2019
647
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. 61
31274701 2019
648
Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels. 61
31078911 2019
649
Anticancer potential of metabolic compounds from marine actinomycetes isolated from Lagos Lagoon sediment. 61
31297298 2019
650
Monte carlo study of organ doses and related risk for cancer in Tanzania from scattered photons in cervical radiation treatment involving Co-60 source. 61
31153393 2019
651
A deadly trap for para-aortic lymph node dissection in patients with horseshoe kidney as a complication: a case report. 61
31109221 2019
652
Cryogel composites based on hyaluronic acid and halloysite nanotubes as scaffold for tissue engineering. 61
30840861 2019
653
Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation. 61
30974190 2019
654
Cytotoxic Effects of Diterpenoid Alkaloids Against Human Cancer Cells. 61
31234546 2019
655
LINC00052 inhibits tumor growth, invasion and metastasis by repressing STAT3 in cervical carcinoma. 61
31210293 2019
656
Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model. 61
30810443 2019
657
Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma. 61
31026210 2019
658
New ternary iron(iii) aminobisphenolate hydroxyquinoline complexes as potential therapeutic agents. 61
31123737 2019
659
Lack of association between methylenetetrahydrofolate reductase C677T polymorphism, HPV infection and cervical intraepithelial neoplasia in Brazilian women. 61
31170928 2019
660
Organometallic ruthenium(II)-arene complexes with triphenylphosphine amino acid bioconjugates: Synthesis, characterization and biological properties. 61
30925428 2019
661
Characterization of a novel glycolipid with a difucosylated H-antigen in human blood group O erythrocytes with monoclonal antibody HMMC-1 and its detection in human uterine cervical carcinoma tissues. 61
31098851 2019
662
The security of radical trachelectomy in the treatment of IA-IIA cervical carcinoma requires further evaluation: updated meta-analysis and trial sequential analysis. 61
31011877 2019
663
Correlation between tumor glucose metabolism and multiparametric functional MRI (IVIM and R2*) metrics in cervical carcinoma: Evidence from integrated 18 F-FDG PET/MR. 61
30390401 2019
664
In Vitro and In Vivo Evaluation of Antitumor Activity of Ligustrum robustum, A Chinese Herbal Tea. 61
29790063 2019
665
Self-Assembled Benznidazole-Loaded Cationic Nanoparticles Containing Cholesterol/Sialic Acid: Physicochemical Properties, In Vitro Drug Release and In Vitro Anticancer Efficacy. 61
31083590 2019
666
Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. 61
31089160 2019
667
Comparison of Minimally Invasive Surgery and Abdominal Surgery Among Patients With Cervical Cancer. 61
31092465 2019
668
Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. 61
30238393 2019
669
Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy. 61
31620623 2019
670
Effect of miR-301a/PTEN pathway on the proliferation and apoptosis of cervical cancer. 61
30943822 2019
671
Synthesis, Structure Revision, and Cytotoxicity of Nocarbenzoxazole G. 61
30958679 2019
672
Transforming activity of an oncoprotein-encoding circular RNA from human papillomavirus. 61
31127091 2019
673
Cytotoxic Effects of Newly Synthesized Heterocyclic Candidates Containing Nicotinonitrile and Pyrazole Moieties on Hepatocellular and Cervical Carcinomas. 61
31121825 2019
674
Cervical cancer awareness and presence of abnormal cytology among HIV-infected women on antiretroviral therapy in rural Andhra Pradesh, India. 61
30813859 2019
675
Investigation of photo-induced electron transfer between amino-functionalized graphene quantum dots and selenium nanoparticle and it's application for sensitive fluorescent detection of copper ions. 61
30771945 2019
676
Molecular characterization, recombinant expression and bioactivity profile of an antimicrobial peptide, Ss-arasin from the Indian mud crab, Scylla serrata. 61
30851450 2019
677
Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy. 61
30907147 2019
678
18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with an